ArticleCancers2019

CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.

Shigeki Suemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.